Skip to Content

Veralox Therapeutics Raises $5.4 Million In Seed Funding

September 12, 2019

Shulman Rogers was pleased to advise our client, Veralox, in their $5.4M capital raise. A biotechnology company based in Frederick, Maryland, Veralox will use the funding to advance the development of first-in-class therapeutics to address unmet medical needs. We were thrilled to play a role in this transaction and very much look forward to their continued growth and success. 

For more information and to access the full press release: